SHANGHAIJuly 29, 2020 / PRNewswire / – Alzheimer’s has been an unsolved mystery to scientists since the first patient was diagnosed over 100 years ago. For different theories, such as For example, although the cholinergic hypothesis, the amyloid cascade hypothesis and the tau protein hypothesis, research advances have been achieved, unfortunately without offering new therapies to patients. In recent years, scientists in Parkinson’s disease, depression, and autism have increasingly focused on the gut-brain axis. At the 34th Alzheimer’s Association International Conference (AAIC), data were presented that link the microbiome to Alzheimer’s disease and GV-971 therapy introduced by Shanghai Green Valley Pharmaceuticals.

As the largest and most influential international conference on dementia science, the AAIC organizes a five-day event on the basic sciences, pathogenesis and other developments in the field of Alzheimer’s. On July 27th the opening meeting of the AAIC on the topic “Microbiome in Alzheimer’s Disease: Pathogenesis and Treatment Implications” (about: “The Microbiome and Alzheimer’s Disease: Pathogenesis and Treatment Consequences”) took place, focusing on the influence of the intestinal flora on the Alzheimer’s disease.

“New research shows that an abnormal microbiome releases inflammatory cells in the periphery, which enter the brain and cause neuroinflammation,” says Jeffrey Cummings, MD, Vice Chair for Research and Research Professor at the Faculty of Brain Health of the UNLV and director of the Center for Neurodegeneration and Translational Neuroscience at the Lou Ruvo Center for Brain Health at the Cleveland Clinic.

Michael Heneka, MD, professor at the German Center for Neurodegenerative Diseases and at the Clinic for Neurodegenerative Diseases and Gerontopsychiatry at the University of Bonn, referred to the influence of the microbiome on activated microglia of the immune system, which interacted with astroglia and other nerve cells and caused neuroinflammation.

Sangram sisodia, Professor of Neuroscience at the University of Chicago, demonstrated by his studies with high-dose antibiotics on mice the modulation of the intestinal flora in amyloid protein deposits and neuroinflammation. He concluded: “The changed microbiome may have a significant impact on behaviors and part of Alzheimer’s neuropathology.”

These research results show that scientists are gradually shifting their focus on research on diseases of the central nervous system to include the connection between the intestinal flora and disorders of the central nervous system.

For example, a study published in the Journal of Physiology on July 2 showed that the build-up of misfolded proteins in the gut in mice could promote the development of signs of Alzheimer’s disease.

Im August 2019 Professor Shengdi Chen of the Shanghai Jiaotong University School of Medicine provided clinical evidence for the correlation between intestinal flora and Alzheimer’s.

On July 27, Professor Meiyu Geng held the Chinese Academy of Sciences at the Shanghai Institute of Materia medica In a AAIC session, a lecture entitled “Causal Communication Between Gut Microbiota Dysbiosis and Neuroinflammation in Alzheimer’s Disease and Therapeutic Intervention by Oligomannate” (for example: “Causal connection between intestinal flora dysbiosis and neuroinflammation in Alzheimer’s and therapeutic intervention by Oligomannat”). The novel mechanism of GV-971, which targets the intestinal-brain axis and was presented by their research team, was explained and demonstrated that GV-971 remedied intestinal flora dysbiosis, prevented an abnormal increase in intestinal flora metabolites, a peripheral and central one Inflammation modulated, amyloid protein deposits reduced and cognitive function improved.

GV-971 is the first novel drug that targets the gut-brain axis for the treatment of Alzheimer’s. It was approved by the NMPA in November 2019 approved and approved by the FDA as an Investigational New Drug for a Phase III global multicenter clinical trial expected to be completed in 2025.

According to data from the World Health Organization, around 50 million people worldwide suffer from dementia, 60-70% of whom have Alzheimer’s. There is still a long way to go before this untreatable disease can be completely overcome. Fortunately, advances in research, drug discovery, and treatment for Alzheimer’s disease are ongoing.